Sanjay has made over 1 trades of the Immunic stock since 2015, according to the Form 4 filled with the SEC. Most recently Sanjay bought 5,000 units of IMUX stock worth $23,000 on 18 August 2015.
The largest trade Sanjay's ever made was buying 5,000 units of Immunic stock on 18 August 2015 worth over $23,000. On average, Sanjay trades about 1,250 units every 0 days since 2015. As of 18 August 2015 Sanjay still owns at least 7,000 units of Immunic stock.
You can see the complete history of Sanjay Patel stock trades at the bottom of the page.
Sanjay's mailing address filed with the SEC is AM KLOPFERSPITZ 19, , MARTINSRIED MUNICH, 2M, 82152.
Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann e Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic executives and other stock owners filed with the SEC include: